Organogenesis Holdings Inc. (ORGO)
| Previous Close | 2.3900 |
| Open | 2.4200 |
| Bid | 2.4600 x 600 |
| Ask | 2.5300 x 100 |
| Day's Range | 2.4100 - 2.5250 |
| 52 Week Range | 1.9600 - 4.7050 |
| Volume | |
| Avg. Volume | 916,157 |
| Market Cap | 329.441M |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | 62.12 |
| EPS (TTM) | 0.0400 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
GlobeNewswireOrganogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six monthsTransformational opportunity for Organogenesis to enter large and growing pain management market with innovative therapyWill address critical unmet medical need for all knee OA patients, including the most severe, if approved CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine com
- GlobeNewswire
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time on May 9th to
- GlobeNewswire
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with t
